南京医药集团股份有限公司 关于公司全称、注册资本变更登记及《公司章程》备案完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 变更后的公司全称：南京医药集团股份有限公司（以下简称"公司"），英文名称变更为"Nanjing Pharmaceutical Group Company Limited"。证券简称、证券代码均保持不变。 证券代码：600713 证券简称：南京医药 编号：ls2025-153 债券代码：110098 债券简称：南药转债 ● 变更后的公司注册资本：1,308,929,289元。 一、本次变更的基本情况 2025年10月29日，公司第十届董事会第四次会议审议通过《关于修订〈南京医药股份有限公司章程〉相 关条款并取消监事会、变更公司全称及注册资本的议案》，同意公司取消监事会，由董事会审计与风险 控制委员会行使《公司法》规定的监事会职权，《南京医药股份有限公司监事会议事规则》相应废止。 同意变更公司全称为"南京医药集团股份有限公司"，英文名称变更为"Nanjing Pharmaceut ...

据天眼查APP显示，瑞康医药集团股份有限公司成立于2004年09月21日，注册资本150471.0471万人民 币。（数据宝） 数据宝统计，截至10:06，瑞康医药成交额10.68亿元，创2022年12月19日以来新高。最新股价上涨 8.52%，换手率20.54%。上一交易日该股全天成交额为3.62亿元。 ...

展望后市，沪指今日回踩3888点附近支撑后未能有效企稳，短期仍处于3850-3950点区间震荡格局；警 惕高估值中小票的流动性风险，以及海外美联储政策预期波动对A股的传导影响。 上证指数收跌0.51%报3878点，深证成指跌0.78%，创业板指跌1.12%，科创50跌0.89%，A股全天成交 1.68万亿元，上日成交1.61万亿元，显示市场分歧有所加大。 医药商业板块近期表现活跃，海王生物6连板涨停。消息面上，近日，中国疾控中心相关负责人介绍本 轮流感最新情况，预计全国在12月上中旬达峰的可能性较大，未来6到8周流感防控不能放松。朱雀三号 遥一运载火箭发射升空并实现二级入轨，虽回收试验失败，但为后续可重复使用技术积累数据，对商业 航天板块形成差异化影响。 《大象财经》 -- 河南卫视财经新主张: 把握最新财经热点,传播权威政策解读, 记录真实财经故事,关注全民消费安全, 架起政企沟通桥梁,助力地方经济腾飞。 ...

（文章来源：每日经济新闻） 每经AI快讯，12月4日，医药商业板块短线走低，人民同泰跌超9%，合富中国、开开实业、建发致新、 达嘉维康等跟跌。 ...

Market Overview - A-shares experienced a week-long rebound but showed signs of adjustment today, with the index briefly surpassing 3900 points before retreating, yet remaining above the five-day moving average [1] - Trading volume decreased from 290 billion to approximately 280 billion, returning to a low level of 1.6 trillion [1] - Over 3700 stocks declined, indicating a growing loss effect in the market [1] Sector Performance - The strongest performing sectors today included pharmaceutical retail, local stocks from Fujian, and defensive consumer sectors like tourism and prepared dishes, which are not the recent focus of institutional investors [3] - The lithium battery sector led declines, indicating a potential weakening trend as it broke below the 30-day moving average, affecting cyclical theme stocks negatively [3] - Technology stocks, particularly those related to artificial intelligence, also showed weakness, suggesting a lack of clear market direction [3] Economic Indicators - Recent PMI data indicated economic weakness, which is a significant concern for the capital market, necessitating strong economic stabilization measures from policymakers [5] - The absence of policy intervention following the PMI release suggests a potential waiting strategy from authorities before implementing new measures [5][7] Future Expectations - Upcoming meetings, including the Central Political Bureau and Central Economic Work Conference, are expected to release favorable policies aimed at stabilizing the economy [7][14] - Market sentiment may remain bullish leading up to these meetings, with expectations that any positive news could further support stock prices [7][14] Global Influences - The anticipation of a potential interest rate cut by the Federal Reserve has increased, with predictions of a 25 basis point reduction due to a weak labor market [9][10] - A Fed rate cut could enhance the attractiveness of Chinese assets, as evidenced by recent rebounds in Chinese concept stocks and the Nasdaq Golden Dragon Index [10] - The Fed's actions may also provide the People's Bank of China with more room for monetary policy adjustments, potentially leading to further easing measures [10][11] Conclusion - The current market adjustment may be a temporary setback, with expectations of a rebound as the market prepares for upcoming policy announcements and potential global monetary easing [14]

Group 1: Style Rotation Insights - The Q4 style rotation model indicates signals for small-cap and growth stocks [2][3] - The dual-driven rotation strategy for Q4 has a composite score of -1, predicting a focus on small-cap stocks [3] - The value-growth style rotation model shows a composite score of -3, suggesting a preference for growth stocks [4] Group 2: Industry Rotation Analysis - In November, the composite factor strategy yielded an excess return of -0.58%, while the single-factor long strategy had an excess return of -0.83% [4] - For December, the recommended long industries based on single-factor strategies include banking, construction, non-bank financials, and electric equipment & new energy [4] - The composite factor strategy recommends long positions in telecommunications, comprehensive finance, computers, electric equipment & new energy, and utilities [4] Group 3: Pharmaceutical Sector Performance - In November 2025, the pharmaceutical sector underperformed the broader market, with the SW pharmaceutical and biological index declining by 3.6% compared to a 1.7% drop in the Shanghai Composite Index [7] - The relative premium level of the pharmaceutical sector is currently at 72.6%, indicating a normal valuation level compared to all A-shares [7] - In the Hong Kong market, the pharmaceutical sector performed similarly to the market, with the Hang Seng Medical Care index at -0.1% and the biotechnology sector at +0.4% [7] Group 4: U.S. Pharmaceutical Market Trends - In November 2025, the U.S. pharmaceutical sector outperformed the broader market, with the S&P Healthcare Select Sector Index rising by 9.1% compared to a 0.1% increase in the S&P 500 [8] - Notable gainers in the S&P 500 healthcare component included Eli Lilly (+25%) and Solventum (+23%) [8]

证券日报网讯 12月3日晚间，南京医药发布公告称，子公司福建同春使用暂时闲置募集资金8，000万元 购买招商银行单位大额存单2025年第4976期，产品期限6个月，年化收益率1.30%，起息日2025年12月3 日，到期日2026年6月3日。 （编辑 袁冠琳） ...

Market Overview - A-shares experienced a decline across the board, with the ChiNext Index dropping over 1% [2] - The Shanghai Composite Index fell by 0.51% to 3878 points, while the Shenzhen Component Index decreased by 0.78% and the ChiNext Index by 1.12% [2] - Total trading volume in the Shanghai and Shenzhen markets reached 168.37 billion yuan, an increase of 76.4 billion yuan from the previous day [2] Sector Performance - The AI application concept saw a pullback, with stocks like Fushi Holdings dropping over 12% and Inspur Software hitting the daily limit down [2] - Conversely, the non-ferrous metals and coal sectors showed resilience, with stocks such as Dayou Energy and Antai Group hitting the daily limit up [2] - The cultivated diamond concept surged, with Sifangda rising over 15% and Huifeng Diamond increasing by more than 10% [2] - The anti-influenza concept was notably active, with Haiwang Biological achieving a six-day limit up and stocks like Jindike and Yuewannianqing rising over 15% [2] Influenza-related Developments - The anti-influenza sector has been active, with Haiwang Biological hitting the limit up for six consecutive days and *ST Changyao also reaching the limit up at 20% [3] - The China CDC reported a nearly 45% positivity rate for influenza-like cases, indicating a significant rise in flu activity, with 17 provinces reaching high epidemic levels [3] - Institutions suggest that the rising flu cases may increase public and market attention, potentially boosting demand for flu prevention and treatment products [3] Company-specific Insights - Hainan Haiyao announced its capability to produce antiviral drugs for influenza, including amantadine hydrochloride tablets [4] - Dajia Weikang reported a significant increase in sales of anti-influenza drugs and is actively preparing to meet market demand [4] - Zhongsheng Pharmaceutical highlighted its integrated supply chain for antiviral drugs, ensuring quality and cost control [5] Stock Movements - Saiwei Electronics experienced a sharp decline, hitting a limit down of 19.56% after a previous 118% increase over the last ten trading days [6] - Hefo China saw a limit down at the end of the trading day, closing at 23 yuan per share after a cumulative increase of over 280% since October 28 [8] - Jinfu Technology, after a series of limit ups, faced a limit down, showcasing a volatile trading pattern [11]

Group 1 - Dongfang Electric announced that three executives plan to reduce their holdings by a total of no more than 30,000 shares due to personal financial needs [1] - Yahu Pharmaceutical's APL-1401 clinical trial data was presented at the 19th European Colorectal Congress, indicating progress in treating moderate to severe ulcerative colitis [1] - Guizhou Bai Ling's actual controller is under investigation by the China Securities Regulatory Commission for insider trading and information disclosure violations [3] Group 2 - Bairen Medical's ePTFE pericardial membrane product has been approved for registration, ending the reliance on imports for this product in the domestic market [4] - Qianxin received approval for a total of 2 billion yuan in technology innovation bonds, with plans to issue medium-term notes and short-term financing bonds [6] - Tengjing Technology's shareholder plans to reduce holdings by no more than 1.96% of the company's shares [7] Group 3 - Yuntianhua's subsidiary is required to pay 386 million yuan in overdue taxes and penalties, which will impact the company's net profit for 2025 [8] - Jianyou Pharmaceutical's propofol emulsion injection has received FDA approval in the United States [9] - Suzhou Gaoxin successfully acquired land use rights for a residential project for 360 million yuan [9] Group 4 - Chalco International's subsidiary won a bid for a 3.03 billion yuan electrolytic aluminum project [11] - Tai Long Pharmaceutical's stock will continue to be suspended due to potential changes in control as the major shareholder is planning a share transfer [12] - Qianli Technology reported a 63.44% year-on-year increase in automobile sales for November, although new energy vehicle sales decreased by 43.98% [13] Group 5 - Fosun Pharma's innovative drug FXS0887 has received approval for a Phase I clinical trial for advanced malignant solid tumors [14] - Guoen Co. has obtained approval for a project to produce 20,000 square meters of aviation-grade acrylic glass, with a total investment of 560 million yuan [15] - Guofa Co.'s chairman resigned due to personal reasons [17] Group 6 - Shanghai Construction won a bid for a state-owned construction land use right for 264 million yuan [18] - Weixin Kang's subsidiary received approval for a clinical trial of lidocaine cream for local anesthesia [20] - Sanxing Medical's subsidiary is a candidate for a 152 million yuan transformer procurement project for the State Grid [20] Group 7 - People's Daily announced the resignation of its president due to work changes, while retaining other leadership roles [21] - Beibu Gulf Port reported a 0.29% year-on-year increase in cargo throughput for November [22] - Chongqing Construction won three engineering projects with a total value of approximately 2.773 billion yuan [23] Group 8 - Xingyu Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange [24] - Huajian Group signed a design contract worth 160 million yuan for a comprehensive project [25] - Wankai New Materials plans to invest 350 million yuan in a technical transformation project for producing 100,000 tons of adipic acid [26] Group 9 - Kaipuyun received a government subsidy of 18 million yuan, which is 87.43% of its net profit for the last audited fiscal year [28] - Ningbo Port expects a 10.8% year-on-year increase in container throughput for November [30] - An Cai High-Tech plans to invest 498 million yuan to upgrade its photovoltaic glass production line [32] Group 10 - Shunhao Co. stated that its existing business has not generated synergies with the rail business, which faces various risks [34] - Yihualu plans to publicly transfer 35% of its stake in Liaoyun Company [35] - ST Wanfang's shareholder plans to reduce holdings by no more than 3% of the company's shares [36] Group 11 - Youyou Food's shareholder plans to reduce holdings by no more than 110,000 shares [38] - Hengtong Optic-Electric's incentive fund has spent 49.98 million yuan to purchase company shares [41] - Zoli Pharmaceutical plans to issue convertible bonds to raise no more than 1.556 billion yuan for various projects [42]

Group 1 - The company, Shuyupingmin (301017.SZ), has stated that it has not yet engaged in any business related to elderly care or medical robots [1] Group 2 - The Food and Beverage ETF (Product Code: 515170) has seen a slight decline of 0.34% over the past five days, with a price-to-earnings ratio of 20.61 times and a total fund flow of 10.88 billion shares, increasing by 1.5 million shares [3] - The Gaming ETF (Product Code: 159869) has increased by 3.10% over the past five days, with a price-to-earnings ratio of 36.59 times [3] - The Sci-Tech 50 ETF (Product Code: 588000) has risen by 1.31% over the past five days, with a price-to-earnings ratio of 148.60 times and a total fund flow of 51.53 billion shares, increasing by 49.5 million shares [3] - The Cloud Computing 50 ETF (Product Code: 516630) has increased by 3.15% over the past five days, with a price-to-earnings ratio of 94.84 times [3]